AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India
Objective: To determine the therapeutic efficacy and safety of AYUSH-64 as an add-on to standard care in mild to moderate COVID-19. Design setting, and interventions: This open-label randomized controlled parallel-group trial was conducted at a designated COVID care centre in India in 80 patients di...
Saved in:
Main Authors: | Harbans Singh (Author), Sumit Srivastava (Author), Babita Yadav (Author), Amit K. Rai (Author), Sophia Jameela (Author), Sanuj Muralidharan (Author), Rijin Mohan (Author), Shikha Chaudhary (Author), Richa Singhal (Author), Rakesh Rana (Author), Shruti Khanduri (Author), Bhagwan S. Sharma (Author), Bhogavalli Chandrasekhararao (Author), Narayanam Srikanth (Author), Sarika Chaturvedi (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ashwagandha (Withania somnifera) and Shunthi (Zingiber officinale) in mild and moderate COVID-19: An open-label randomized controlled exploratory trial
by: Harbans Singh, et al.
Published: (2023) -
Disease Characteristics, Care-Seeking Behavior, and Outcomes Associated With the Use of AYUSH-64 in COVID-19 Patients in Home Isolation in India: A Community-Based Cross-Sectional Analysis
by: Narayanam Srikanth, et al.
Published: (2022) -
AYUSH for COVID-19: Science or Superstition?
by: Ritu Priya, et al.
Published: (2020) -
National Education Policy 2020 and Ayush
by: Sanjeev Sharma
Published: (2022) -
In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19
by: Siva Swapna Kasarla, et al.
Published: (2022)